Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Key Points
- Teva Pharmaceutical Industries Ltd (TEVA) reported strong growth in its innovative portfolio, with key products like AUSTEDO, AJOVY, and UZEDY showing significant year-over-year increases.
- The company successfully executed its Pivot to Growth strategy, focusing on delivering growth engines, stepping up innovations, sustaining its generics powerhouse, and focusing the business.
- Teva Pharmaceutical Industries Ltd (TEVA) announced the acquisition of Emalex Bioscience, which aligns with its growth strategy and adds a promising asset for treating Tourette syndrome.
- The company reported a 76% increase in free cash flow, reaching $200 million, and maintained a strong balance sheet with a net debt to EBITDA ratio of 2.42x.
- Teva Pharmaceutical Industries Ltd (TEVA) is on track to achieve its 2027 financial targets, including a 30% operating margin and significant cost savings from its transformation programs.
- Teva Pharmaceutical Industries Ltd (TEVA) experienced a 1% decline in overall revenue, attributed to the decrease in generic revenues, including the impact of generic Revlimid.
- The company faces challenges in the generics market, with a 13% decline in generics revenue, excluding Japan, and a flat performance when excluding both Japan and generic Revlimid.
- There is uncertainty regarding the impact of the Inflation Reduction Act (IRA) on AUSTEDO's inventory and pricing dynamics in the fourth quarter of 2026.
- Teva Pharmaceutical Industries Ltd (TEVA) anticipates higher operating expenses related to the Emalex acquisition, which will affect its 2026 financial guidance.
- The geopolitical situation in the Middle East poses potential risks, although the company reported no material impact on its operations or 2026 guidance so far.
Hello, and welcome to the Teva Pharmaceutical Industries Limited Q1 2026 earnings conference call. My name is Alex. and I'll be coordinating today's call. (Operator Instructions).
I'll now hand it over to Christopher, SVP, Investor Relations. Please go ahead.
Thank you, Alex. Good morning and good afternoon, everyone. Thank you for joining us on our first quarter call. I'd like to note that before we posted our press release this morning on earnings, we also posted a press release on the Emalex transaction as well as the slide deck relating to that transaction. And you can find those materials in the same section as you can find our earnings materials.
Before I turn the call over to our CEO, Richard Francis, I want to remind everyone that we will be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
